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Abstract
In this study, we established systemic in-vivo evidence from molecular to organism level to explain
how diabetes can aggravate myocardial ischemia-reperfusion (I/R) injury and revealed the role of
insulin signaling (with specific focus on Akt/GLUT4 signaling molecules). The myocardial I/R injury
was induced by the left main coronary artery occlusion for 1 hr and then 3 hr reperfusion in
control, streptozotocin (STZ)-induced insulinopenic diabetes, and insulin-treated diabetic rats. The
diabetic rats showed a significant decrease in heart rate, and a prolonged isovolumic relaxation
(tau) which lead to decrease in cardiac output (CO) without changing total peripheral resistance
(TPR). The phosphorylated Akt and glucose transporter 4 (GLUT 4) protein levels were
dramatically reduced in both I/R and non-I/R diabetic rat hearts. Insulin treatment in diabetes
showed improvement of contractile function as well as partially increased Akt phosphorylation and
GLUT 4 protein levels. In the animals subjected to I/R, the mortality rates were 25%, 65%, and 33%
in the control, diabetic, and insulin-treated diabetic group respectively. The I/R-induced
arrhythmias and myocardial infarction did not differ significantly between the control and the
diabetic groups. Consistent with its anti-hyperglycemic effects, insulin significantly reduced I/R-
induced arrhythmias but had no effect on I/R-induced infarctions. Diabetic rat with I/R exhibited
the worse hemodynamic outcome, which included systolic and diastolic dysfunctions. Insulin
treatment only partially improved diastolic functions and elevated P-Akt and GLUT 4 protein levels.
Our results indicate that cardiac contractile dysfunction caused by a defect in insulin-stimulated
Akt/GLUT4 may be a major reason for the high mortality rate in I/R injured diabetic rats.
Background
Diabetes mellitus is the world's fastest-growing disease
with high morbidity and mortality rates predominantly as
results of cardiovascular diseases [1,2]. Prospective studies
have documented increased likelihood of sudden cardiac
death and unrecognized myocardial infarctions in
patients with diabetes [3]. Moreover, acute ischemic syn-
dromes, peripheral arterial disease, and advanced cardio-
vascular disease (CVD) complications occur more
commonly in patients with diabetes than in those without
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[3]. Despite the prevalence and the significant impact this
disease has on our world today, the understanding of the
cellular and molecular perturbations that predispose to
altered myocardial structure and function remains incom-
plete. Recently, it has been speculated that myocardial
insulin resistance develops in animal models of both type
1 and type 2 diabetes [4]. Various studies to date indicate
multiple sites of impaired insulin signaling in various ani-
mal models; all the findings clearly support the existence
of myocardial insulin resistance [4]. Insulin-stimulated
glucose uptake, protein synthesis and glycogen synthesis
have been shown to be reduced in the heart and cardio-
myocytes of diabetic rats [5,6].
Insulin regulates metabolism in the heart by modulating
glucose transport, glycolysis, glycogen synthesis, lipid
metabolism, protein synthesis, growth, contractility, and
apoptosis in cardiomyocytes [7-9]. In addition, vasodila-
tor actions of insulin in coronary vasculature augment
myocardial perfusion [10]. As in other insulin-sensitive
tissues, insulin signaling via PI3K/Akt pathways plays a
key role in cardiac glucose uptake [7]. Insulin resistance is
an important risk factor for the development of hyperten-
sion, atherosclerotic heart disease, left ventricular hyper-
trophy and dysfunction, and heart failure [11]. It reflects a
disturbance of glucose metabolism and can potentially
worsen metabolic efficiency of cardiomyocytes. During
insulin resistance or diabetes, the heart rapidly modifies
its energy metabolism to decrease glucose utilization and
increase fatty acid consumption. Accumulating evidence
suggests that this alteration of cardiac metabolism plays
an important role in the development of cardiomyopathy
[11]. Heart disease is the leading cause of death in diabetic
patients [12], with coronary artery disease (CAD) and
atherosclerosis being the primary reasons for increased
incidence of cardiovascular dysfunction [12,13]. A predis-
position to heart failure might also reflect the effects of
underlying abnormalities in cardiac diastolic function
that can be detected in asymptomatic patients with diabe-
tes [14,15]. Several etiological factors have been put for-
ward to explain why hyperglycemia and/or diabetes tend
to lead to diabetic cardiomyopathy. However, the under-
lying mechanisms are not yet fully understood. Therefore,
this study aims to investigate the mechanisms of diabetes
which causes cardiac dysfunctions in STZ-diabetic rats
with and without myocardial I/R injuries. Our study
yielded systemic in-vivo evidence in different structural
levels to explain how diabetes aggravate myocardial I/R
injury and reveal the role of insulin signaling.
Materials and methods
Experimental Diabetic Animals
This investigation abides by the rules written in the Guide
for the Care and Use of Laboratory Animals, published by
the US National Institutes of Health (NIH publication No.
85-23, revised 1996). Eight week-old Sprague-Dawley
(SD) rats (body weight from 250 gm to 300 gm) were
maintained in the Animal Center of the Chang Gung Uni-
versity, under an ambient temperature of 25 ± 1°C and a
light-dark period of 12 hrs. The animals were fed with
normal chow and water.
To induce diabetes, male SD rats were fasted and anesthe-
tized by intraperitoneal injection of pentobarbital with a
dosage of 65 mg/kg. The animals were then injected with
a single intravenous injection of freshly prepared strepto-
zotocin (STZ, 65 mg/kg). STZ has been shown to destroy
pancreatic β-cells and induce a diabetic state during the
first 24 h after injection [16]. Two weeks later, blood sugar
levels were measured by the glucose oxidase method
(Chemistry Analyzer; Auto analyzer Quik-Lab., Ames,
Spain). Animals with blood sugar levels above 300 mg/dl
and symptoms of polyphagia, polyuria and polydipsia
were classified as being induced to diabetes. Age-matched
rats were used as nondiabetic controls.
Myocardial I/R Injury
SD rats were anesthetized with inactin (100 mg/kg i.p.)
and urethane (400 mg/kg i.p.). Myocardial ischemia was
performed by a temporary tightening of the silk ligature
around the left main coronary artery as previously
described [17,18]. Reperfusion was achieved by releasing
the tension applying to the ligature (operated groups).
Sham operated animals underwent all the same surgical
procedures, except for the silk that passes around the left
coronary artery being not tied (sham groups). Before and
during the ischemia and reperfusion period, heart rate
(HR), blood pressure (BP) and ECG changes were
recorded. Ventricular ectopic activity was evaluated
according to the diagnostic criteria advocated on the Lam-
beth Convention [19]. The incidence and duration of ven-
tricular tachyarrhythmias, including ventricular
tachycardia (VT) and ventricular fibrillation (VF), in the
surviving animals were documented.
Myocardial Infarction
Areas of infarction and perfusion were determined by the
triphenyl tetrazolium chloride-Evan's blue technique
[20]. At the end of the experiments, the coronary artery
was re-occluded and 2.0 ml methyl blue (3%) was
injected intravenously to mark the area at risk. The heart
was then excised and the atria were removed. The ven-
tricular tissue was sliced into 1 mm sections and incu-
bated in tetrazolium dye (1% 2, 3, 5-triphenyltetrazolium
chloride/0.9% NaCl, pH 7.4) at 37°C for 40 minutes. Sec-
tions were then placed in 10% formaldehyde in saline for
2 days before infarct (white) tissue was excised. The infarct
tissue was quantified as percentage of occluded zone.Journal of Biomedical Science 2009, 16:77 http://www.jbiomedsci.com/content/16/1/77
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Hemodynamic Measurements
The animals were anesthetized with inactin (100 mg/kg
i.p.) and urethane (400 mg/kg i.p.) then placed on con-
trolled heating pads (TC-1000 Temperature Controller,
CWE Inc. USA) with the core temperature measured via a
rectal probe maintained at 37°C. A microtip pressure-vol-
ume catheter (SPR-838; Millar Instruments, Houston, TX)
was inserted into the right common carotid artery and
advanced into the left ventricle (LV) under pressure con-
trol as described [21-23]. Polyethylene cannulas (PE-50)
were inserted into the right femoral artery for the meas-
urement of mean arterial pressure (MAP). After stabilizing
for 20 min, the signals were continuously recorded at a
sampling rate of 1,000/s by using an ARIA pressure-vol-
ume (P-V) conductance system (Millar Instruments) cou-
pled to a Powerlab/4SP analog-to-digital converter (AD
Instruments, Mountain View, CA). Data was displayed
and recorded on a computer. All P-V loop data were ana-
lyzed by using a cardiac P-V analysis program (PVAN3.2;
Millar Instruments), and the heart rate (HR), end-systolic
volume (ESV), end-diastolic volume (EDV), end-systolic
pressure (ESP), end-diastolic pressure (EDP), stroke vol-
ume (SV), ejection fraction (EF), cardiac output (CO),
stroke work (SW), arterial elastance (Ea; end-systolic pres-
sure/SV), mean arterial pressure (MAP), maximal slope of
systolic pressure increment (max dP/dt), and diastolic
decrement (min dP/dt) were computed. The relaxation
time constant (tau), an index of diastolic function, was
calculated by two different methods [Weiss method:
regression of log (pressure) versus time and Glantz
method: regression of dP/dt vs. pressure] using PVAN3.2.
Total peripheral resistance (TPR) was calculated by the
following equation: TPR = MAP/CO. The hemodynamic
parameters were also determined under conditions of
changing preload, elicited by transiently compressing the
inferior vena cava (IVC) using a cotton swab inserted
through a small, transverse, upper abdominal incision.
This technique yields reproducible occlusions in animals
without opening the chest cavity. Because max dP/dt may
be preload dependent, the P-V loops recorded at different
preloads were used to derive other useful systolic function
indexes that may be less influenced by loading conditions
and cardiac mass. These measurements include dP/dt-end
diastolic volume (EDV) relation (dP/dt-EDV), end-systo-
lic PV relation [maximum chamber elasticity (ESPVR),
Emax], and the preload-recruitable stroke work (PRSW),
which represents the slope between SW and EDV and is
independent of chamber size and mass. The slope of the
end-diastolic PV relationship (EDPVR), an index of LV
stiffness, was also calculated from P-V relations using
PVAN 3.2.
Immunoblotting
Tissue lysates (membranous and cytoplasmic fraction)
were isolated from cardiac tissues in accordance to previ-
ously published procedure with slight modifications [24].
In brief, tissues were first homogenized in a lysis buffer
(M-PER; Pierce, USA) with 1 mM phenylmethylsulfo-
nylfluoride (PMSF) as a protease inhibitor. The tissue
lysates were then ultracentrifuged at 50,000 rpm for 1 h at
4°C. The resulting supernatant was labeled as a cytoplas-
mic fraction. The resulting pellet, which contained the
crude membrane, was re-suspended in M-PER (300~500
μl) with 0.5% Triton X-100, incubated at 4°C overnight,
and centrifuged again at 15,700 g for 20 min. Finally, the
supernatant was collected and labeled as a membrane
fraction. Protein samples of cytoplasmic and membra-
nous lysates were subjected to 10% SDS-PAGE and elec-
trophoretically transferred to PVDF protein sequencing
membrane for 2 hrs. The membrane was blocked in 5%
non-fat milk in Tris-buffered saline with 0.1% Tween-20
(TBST). It was then washed and blotted with anti-GLUT1
(Chemicon, USA) and GLUT4 (Chemicon, USA). Phos-
phorylation of Akt was detected with anti-phospho-Akt
(Ser473) and anti-phospho-Akt (Thr308) (Santa Cruz);
Akt was determined with anti-Akt antibody (Santa Cruz).
The membrane was then incubated with HRP-conjugated
secondary antibody prior to chemiluminescence detec-
tion (Pierce, USA).
Statistical Analysis
The difference in BP and HR, duration of VT and VF, inf-
arct size, GLUTs, and Akt protein levels between control,
diabetic, and insulin treated diabetic groups were ana-
lyzed by Student's t-test. The difference in the mortality
rate was analyzed with a Chi-square test. P < 0.05 was used
as criteria for statistical significance.
Results
The Influences of Hyperglycemia on Cardiovascular 
System
Male SD rats were intravenously injected with streptozo-
tocin (STZ) to induce insulinopenic diabetes which was
characterized by elevations in plasma glucose level above
300 mg/dl and by exhibiting symptoms of polyphagia,
polyuria, and polydipsia. Animals treated with STZ
resulted in consistent hyperglycemia and hypoinsuline-
mia that persisted over the 3 week period. Plasma glucose
level in diabetic rats was 606 ± 16 mg/dl compared with
values of 169 ± 4 mg/dl in age-matched controls, P  <
0.001. As expected, the diabetic rats had lower body
weights and ventricular weights compared to age-matched
controls. Body weight loss and hyperglycemia induced by
diabetes were markedly restored by insulin treatment of 5
days (Table 1). Diabetic rats also showed a lower MAP and
a higher heart to body weight ratio than age-matched con-
trols. Insulin treatment not only affected metabolic
parameters (including reduced plasma glucose level and
attenuated body weight loss) but also significantly ele-Journal of Biomedical Science 2009, 16:77 http://www.jbiomedsci.com/content/16/1/77
Page 4 of 13
(page number not for citation purposes)
vated MAP as shown in the comparison between the two
groups (Table 1).
Hyperglycemia and hypoinsulinemia may have divergent
or distinct effects on the progression of cardiomyopathy
in STZ-diabetic rats. We sought to directly measure the
cardiac performance by Millar pressure-volume instru-
ments. The effects of diabetes and insulin treatment on
basic hemodynamic variables are shown in Table 2.
Induction of insulin-deficient diabetes for 3 weeks
decreased basal heart rate (HR) by 16.3%, cardiac output
(CO) by 27.3% and prolonged relaxation time constant
(tau, an index of diastolic function) by 17.4% under basal
condition. The slope of ESPVR (end-systolic elastance,
Ees; indicator of left ventricular contractility) was also
decreased by 28.5% in diabetic rats. The maximum pres-
sure (peak LV pressure), end diastolic pressure (EDP) and
estimated peak isovolumic pressure (P@dPdt max) was
not altered. The diabetes-induced slower HR and lower
CO were reversed by 1 week of insulin treatment. Addi-
tionally, insulin treated diabetic rats showed an increase
in EDP (36.2%) and peak LV pressure (11.4%), and a rise
of 9.9% in estimated peak isovolumic pressure (Table 2).
The Effects of Diabetes on I/R-induced Mortality Rate and 
Rhythm Disturbances
In the control (n = 18) and diabetic (n = 37) groups, the
I/R-induced mortality rates were 25% and 64.5% respec-
tively (P  < 0.05). Consistent with antihyperglycemic
effect, insulin significantly reduced I/R-induced mortality
rate from 64.5% to 33.3% (P < 0.05, n = 15).
In the control group, severe ventricular arrhythmias began
67 minutes after coronary artery occlusion, peaked
around 812 minutes, and subsided at approximately 15
minutes. The duration of VF was calculated to be 45.35 ±
26.15 seconds, and the duration of VT was 41.1 ± 28.17
seconds (Figure 1). During the 1 h ischemia period, the
Table 1: Laboratory characteristics in age-matched control, diabetic (DM), and insulin-treated diabetic (DMI) rats.
Control (n = 21) DM (n = 36) DMI (n = 25)
Plasma glucose (mg/dl) 169 ± 4 607 ± 16*(P < 0.001) 397 ± 24†(P < 0.001)
Plasma insulin (μg/L) 2.7 ± 0.22 1.08 ± 0.16*(P < 0.001) 3.29 ± 0.27†(P < 0.001)
Body weight (g) 411 ± 13 235 ± 5*(P < 0.001) 252 ± 5†(P < 0.05)
Heart weight (g) 1.32 ± 0.05 0.89 ± 0.03*(P < 0.001) 0.97 ± 0.03†(P < 0.05)
Ratio heart/body weight (mg/g) 3.51 ± 0.008 3.91 ± 0.012*(P < 0.001) 3.85 ± 0.013
MAP (mmHg) 118 ± 5 94 ± 4*(P < 0.001) 108 ± 5†(P < 0.05)
TPR (mmHg/ml/min) 2.21 ± 0.1 2.42 ± 0.09 2.21 ± 0.1
Data are expressed as means ± SEM (*, vs. control; †, vs. DM). DM, STZ-diabetes; DMI, insulin-treated diabetes; MAP, mean arterial pressure; TPR, 
total peripheral resistance.
Table 2: Baseline hemodynamic parameters in age-matched control, diabetic (DM), and insulin-treated diabetic (DMI) rats measured 
by Millar pressure-volume conductance catheter system.
Control (n = 24) DM (n = 28) DMI (n = 21)
Heart rate (bpm) 392 ± 7 328 ± 8*(P < 0.01) 352 ± 8†(P < 0.05)
End-systolic volume (μL) 194 ± 16 183 ± 16 185 ± 14
End-diastolic volume (μL) 292 ± 19 256 ± 14 254 ± 15
Maximum pressure (mmHg) 110 ± 3.8 114 ± 3.8 127 ± 5.1†(P < 0.05)
Minimum pressure (mmHg) 2.49 ± 0.62 1.87 ± 0.26 3.22 ± 0.36†(P < 0.01)
End-systolic pressure (mmHg) 101 ± 3.9 109 ± 4.2 122 ± 5.4
End-diastolic pressure (mmHg) 5.66 ± 0.56 5 ± 0.32 6.81 ± 0.5†(P < 0.01)
Stroke volume (μL) 136 ± 12.5 118 ± 7.1 139 ± 7.8
Ejection fraction (%) 43.7 ± 3.14 44.5 ± 2.87 48.4 ± 2.38
Cardiac output (μL/min) 53,414 ± 5,133 38,810 ± 2,712*(P < 0.05) 48,765 ± 2,942†(P < 0.05)
Stroke work (mmHg*μL) 11,088 ± 1,837 9,073 ± 785 11,025 ± 824
Arterial elastance (mmHg/μL) 0.93 ± 0.12 1.03 ± 0.08 0.95 ± 0.07
End-systolic elastance (mmHg/μL) 0.94 ± 0.09 0.67 ± 0.07*(P < 0.05) 0.63 ± 0.05
dPdt max (mmHg/sec) 7,534 ± 460 7,773 ± 389 8,899 ± 388
dPdt min (mmHg/sec) -8,192 ± 600 -7,144 ± 376 -7,960 ± 413
P@dPdt max (mmHg) 74 ± 3.7 75 ± 2.3 82 ± 2.7†(P < 0.05)
Tau_w (msec) 10.33 ± 0.35 12.13 ± 0.33*(P < 0.01) 11.344 ± 0.28
Tau_g (msec) 11.9 ± 0.36 14.76 ± 0.55*(P < 0.01) 14.68 ± 0.7
Data are expressed as means ± SEM (*, vs. control; †, vs. DM). DM, STZ-diabetes; DMI, insulin-treated diabetes.Journal of Biomedical Science 2009, 16:77 http://www.jbiomedsci.com/content/16/1/77
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The effects of diabetes on I/R-induced ventricular rhythm disturbances including VPC (A), VT (B), and VF (C) were determined  during ischemic period (1 h) in the age-matched controlled (n = 7), STZ-diabetic (n = 28), and insulin-treated diabetic (n = 9)  rats Figure 1
The effects of diabetes on I/R-induced ventricular rhythm disturbances including VPC (A), VT (B), and VF (C) 
were determined during ischemic period (1 h) in the age-matched controlled (n = 7), STZ-diabetic (n = 28), 
and insulin-treated diabetic (n = 9) rats. Data were expressed as means ± SEM, # P < 0.05 vs. DM. C, age-matched con-
trol; CS, control sham; DM, STZ-induced diabetes; DMS, DM sham; DMI, diabetes treated with insulin (4 IU/day for 5 days); 
DMIS, DMI sham; I/R, myocardial ischemia 1 h following by a 3 h of reperfusion; VPC, ventricular premature complexes; VT, 
ventricular tachycardia; VF, ventricular fibrillation.
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numbers of ventricular premature complexes (VPC) was
80.57 ± 21.25. Amongst the 7 rats in the control group, 3
animals (42.86%) exhibited VF, and 6 animals (85.71%)
exhibited VT (Figure 1). There was no significant differ-
ence between the severities of the arrhythmias between
the groups. However, diabetic rats treated with insulin
resulted in a decrease of the duration of VT and VF from
34.3 ± 15.6 and 43.7 ± 14.9 to 4.22 ± 1.17 and 3.83 ± 2.75
seconds respectively (Figure 1).
The Effects of Diabetes on I/R-induced Myocardial 
Infarction
The ischemic area and infarct size were estimated after 60
minutes of ischemia and 3 hours of reperfusion. Between
the experimental groups, there were no significant differ-
ences in the size of area at risk (Figure 2A), indicating that
similar amount of tissue was jeopardized by the occlusion
of the left coronary artery in each group. After I/R, the
necrotic area make up 53.65 ± 10.79% and 46.93 ± 7.39%
of the area at risk in the control and diabetic groups
respectively. Insulin treatment did not yield any improv-
ing effects on I/R-induced infarct size when compared to
the diabetic group (Figure 2B).
The Effects of Diabetes on I/R-induced Hemodynamic 
Changes
The effects of insulin-deficient diabetes on I/R-induced
hemodynamic variables are shown in Table 3. In the con-
trol group, animals subjected to I/R had a reduction of
peak LV pressure, ejection fraction, CO, maximal slope of
systolic pressure increment (dP/dt max), diastolic decre-
ment (dP/dt min), and estimated peak isovolumic pres-
sure (Table 2 and 3). In the STZ-diabetic group, I/R-
decreased cardiac contractility was exacerbated more in
diabetic rats than in non-diabetic controls (Table 3); these
effects were partially antagonized by 5 days Insulin treat-
ment. Insulin-treated diabetic rats exhibited a significant
rise of 69.8% in Ees (load-independent index of contrac-
tility) and a shortening of 39.9% in relaxation time con-
stant (tau_g) compared with diabetic rats (Table 3).
The Effects of Diabetes and I/R injury on Glucose 
Transporters (GLUTs) Membrane Translocation and Akt 
Phosphorylation
The membranous and cytoplasmic GLUTs protein levels
were examined by immunoblotting method in experi-
mental rat heart with and without I/R injuries respec-
tively. Diabetic rats had a dramatic reduction of
cytoplasmic GLUT1 protein levels in both I/R and non-I/
R rat hearts compared to the controls (Figure 3). In con-
trast, the membranous GLUT1 protein levels were not sig-
nificantly different between the groups. The cytoplasmic
and membranous GLUT4 protein levels were significantly
reduced in both I/R and non-I/R diabetic rat hearts. Insu-
lin only partially reversed the diabetic effects on GLUT4
protein expression in STZ-diabetic rat hearts (Figure 4).
Notably, with the exception of the insulin-treated group,
I/R also dramatically elevated membranous GLUT4 pro-
tein levels compared to the sham-control group (Figure
4).
Under pathological conditions such as diabetes and myo-
cardial ischemia, insulin signal transduction pathways,
such as phosphatidylinositol 3-kinase/protein kinase B
(Akt) signaling, are clearly modified [25,26]. Cardiac Akt
protein expression and phosphorylation levels were
examined in age-matched control, STZ-diabetic, and insu-
lin-treated diabetic rats with and without I/R injuries. In
the non-I/R heart, diabetes significantly reduced the level
of phosphorylated Akt (P-Thr 308-Akt and P-Ser 473-Akt)
protein compared to age-matched controls, while treat-
ment of insulin yielded a higher phosphorylated Akt (P-
Thr 308-Akt) level in comparison to the diabetic group
(Figure 5). Under myocardial I/R injury, the capacity for
Akt phosphorylation is impaired in insulin-deficient dia-
betes, and treatment of insulin failed to further induce the
phosphorylation level of Akt (Figure 5).
Discussion
The main findings of the study are as follows: (1) In STZ-
induced hyperglycemic and hypoinsulinemic rats, the
phosphorylated Akt and membranous GLUT4 protein lev-
els were markedly reduced in the heart, suggesting that
insulin-stimulated Akt/GLUT4 signaling was impaired in
STZ-induced insulin-deficient diabetes. (2) The defect of
insulin-stimulated Akt/GLUT4 signaling parallels with
ventricular contractile dysfunctions, bradycardia, and
hypotension in STZ-diabetic rats. These detrimental
effects were partially reversed by 5 days of insulin treat-
ment. (3) In animals subjected to acute myocardial I/R
injury, a higher mortality rate was seen in the diabetic
group and this phenomenon coincided with ventricular
contractile dysfunctions, but not with arrhythmias or
myocardial infarction since VT, VF, and necrotic area were
not exacerbated in diabetic heart. (4) Acute myocardial I/
R injury in diabetic rats markedly reduced cardiac output
subsequent to bradycardia and reduction of contractility
(including reduced end-systolic pressure, maximal slope
of systolic pressure increment, and load-independent
index of contractility). These alterations may be the lead-
ing causes of the high mortality rate in diabetic rats. (5)
During the period of acute myocardial I/R injury, the dia-
betes-induced high mortality rate was almost completely
prevented by insulin treatment. This beneficial effect of
insulin may be related to the amelioration of I/R-induced
arrhythmias and cardiac contractile function. On the
other hand, the I/R-induced myocardial infarction (MI)
was not attenuated by insulin treatment. Thus suggesting
MI was not directly involved in the high mortality rate in
diabetes.Journal of Biomedical Science 2009, 16:77 http://www.jbiomedsci.com/content/16/1/77
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The effects of diabetes on I/R-induced myocardial infarction were evaluated in the age-matched controlled (n = 7), STZ-dia- betic (n = 10), and insulin-treated diabetic (n = 9) rats Figure 2
The effects of diabetes on I/R-induced myocardial infarction were evaluated in the age-matched controlled (n 
= 7), STZ-diabetic (n = 10), and insulin-treated diabetic (n = 9) rats. SD rats were subjected to 1 h of left coronary 
artery occlusion and 3 h of reperfusion. The level of myocardial infarction was determined by the triphenyl tetrazolium chlo-
ride-Evan's blue technique. (A) Ratio of area at risk to total ventricle. (B) Ratio of infarct size to area at risk. Data were 
expressed as mean ± SE. C, age-matched control; CS, control sham; DM, STZ-induced diabetes; DMS, DM sham; DMI, diabetes 
treated with insulin (4 IU/day for 5 days); DMIS, DMI sham; I/R, myocardial ischemia 1 h following by a 3 h of reperfusion.
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Under physiological conditions, insulin regulates metab-
olism in the heart by modulating glucose transport, glyc-
olysis, glycogen synthesis, lipid metabolism, protein
synthesis, growth, contractility, and apoptosis [4,27,28].
In the present study, we used STZ (a most common islet
cell toxin) to induce development of type 1 diabetes in SD
rat. The metabolic features of STZ-diabetic rats include the
prompt development of profound hyperglycemia (607 ±
16 mg/dl, Table 1)) and markedly reduced plasma insulin
levels (1.08 ± 0.16 μg/L, Table 1). As such, the experimen-
tal animal model is particularly useful in examining the
myocardial effects of hyperglycemia in the absence of
hyperinsulinemia.
It is generally accepted that cardiac tissue obtains its
energy via oxidation of various substrates like fatty acid
(FA), glucose, lactate, and ketone bodies [29,30]. This
flexibility in substrate selection is essential for the heart to
maintain production of energy and contractile function.
STZ-induced reduction in insulin would cause a compen-
satory shift in myocardial preference for fatty acids in the
absence of insulin mediated glucose uptake. This leads to
cardiac metabolism alterations and eventually impair-
ment of contractile function [31,32]. Additionally, insu-
lin-stimulated glucose uptake in cardiomyocytes is
mediated primarily by the insulin responsive GLUT4.
However, in addition to the basal cardiac glucose uptake
mediated by GLUT1, contraction-mediated GLUT4 trans-
location to the sarcolemma may significantly contribute
to myocardial glucose uptake [33]. As in other insulin-
sensitive tissues, insulin signaling via PI3K/Akt pathways
plays a key role in the regulation of GLUT4 translocation
from cytoplasm to plasma membrane and subsequently
in cardiac glucose uptake [34,35]. In the present study, the
STZ-induced insulin deficient and hyperglycemic rat heart
showed a reduction of Akt phosphorylation and GLUT4
translocation to plasma membrane as well as a decline in
ventricular contractile functions. The diabetes-induced
alterations on molecular (Akt/GLUT4) and organ levels
(ventricular contractility) were seen in both I/R and non-
I/R injured heart. Although treatment with insulin signif-
icantly re-established insulin-stimulated Akt/GLUT4 sign-
aling and improved ventricular contractile function in
basal (non-I/R) condition, insulin had a slight reverse
effect in I/R injured diabetic rat heart. Whether or not the
diabetes-decreased GLUT4 translocation to the plasma
membrane was simply a result from insulin signaling defi-
ciency or was an impairment of contraction-mediated
GLUT4 translocation involved still needs to be clarified
since diabetes also reduced ventricular contractility.
It has been shown that acidosis produced by myocardial
ischemia provokes the inhibition of the tyrosine kinase
activity of insulin receptor. This inhibition directly corre-
lates to the decrease in phosphorylation of different ele-
ments downstream including PKB/Akt, p70S6K, and GSK-
3 [36]. Even if the insulin signaling pathways were
blunted during ischemia, insulin would still be able to act
during reperfusion. Our result shows that myocardial I/R
markedly increased GLUT4 translocation to plasma mem-
brane, but had no effect on Akt phosphorylation in con-
trol animals without diabetes. This data may provide
indirect evidence to suggest that glucose uptake was
increased in I/R injured heart since membranous GLUT4
Table 3: I/R-induced hemodynamic changes in age-matched control, diabetic (DM), and insulin-treated diabetic (DMI) rats measured 
by Millar pressure-volume conductance catheter system.
Control (n = 7) DM (n = 9) DMI (n = 8)
Heart rate (bpm) 366 ± 12 263 ± 12*(P < 0.001) 299 ± 12
End-systolic volume (μL) 253 ± 42 233 ± 35 219 ± 37
End-diastolic volume (μL) 311 ± 45 286 ± 32 279 ± 39
Maximum pressure (mmHg) 90 ± 3 71 ± 4.4*(P < 0.01) 75 ± 4.4
Minimum pressure (mmHg) 2.54 ± 0.46 1.74 ± 0.4 2.86 ± 1.86
End-systolic pressure (mmHg) 87 ± 2.9 66 ± 4.9*(P < 0.01) 70 ± 3.9
End-diastolic pressure (mmHg) 6.98 ± 0.92 4.9 ± 0.41*(P < 0.05) 6.76 ± 2.02
Stroke volume (μL) 94 ± 13 84 ± 9.2 92 ± 9.3
Ejection fraction (%) 30.8 ± 4.53 31.3 ± 4.44 33.4 ± 3.95
Cardiac output (μL/min) 33,914 ± 4,240 22,504 ± 3,263*(P < 0.05) 27,342 ± 2,848
Stroke work (mmHg*μL) 5,501 ± 914 4,031 ± 601 4,640 ± 720
Arterial elastance (mmHg/μL) 1.04 ± 0.15 0.9 ± 0.17 0.82 ± 0.07
End-systolic elastance (mmHg/μL) 0.893 ± 0.179 0.484 ± 0.071*(P < 0.05) 0.822 ± 0.166
dPdt max (mmHg/sec) 4,956 ± 292 3,738 ± 298*(P < 0.05) 4,523 ± 639
dPdt min (mmHg/sec) -3,944 ± 279 -3,002 ± 414 -3,054 ± 303
P@dPdt max (mmHg) 49.53 ± 3.25 39.19 ± 2.93 42.91 ± 4.54
Tau_w (msec) 11.44 ± 0.86 16.71 ± 1.29*(P < 0.1) 13.51 ± 1.45
Tau_g (msec) 14.73 ± 1.65 24.07 ± 0.92*(P < 0.05) 16.62 ± 0.71†(P < 0.05)
Data are expressed as means ± SEM (*, vs. control; †, vs. DM). DM, STZ-diabetes; DMI, insulin-treated diabetes.Journal of Biomedical Science 2009, 16:77 http://www.jbiomedsci.com/content/16/1/77
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The influences of diabetes on cytoplasmic and membranous GLUT1 protein level were examined in the age-matched control- led, STZ-diabetic, and insulin-treated diabetic rats with or without I/R injury Figure 3
The influences of diabetes on cytoplasmic and membranous GLUT1 protein level were examined in the age-
matched controlled, STZ-diabetic, and insulin-treated diabetic rats with or without I/R injury. Equal amounts of 
proteins were resolved on 10% SDS-PAGE and blotted with respective GLUT1 antibodies. All experiments were performed in 
triplicates from six animals (*, vs. CS; ‡, vs. C; n = 6 per group). The upper panels show blots and the lower panels show quan-
tified ratio. C) age-matched control; CS, control sham; DM, STZ-induced diabetes; DMS, DM sham; DMI, diabetes treated with 
insulin (4 IU/day for 5 days); DMIS, DMI sham; I/R, myocardial ischemia 1 h following by a 3 h of reperfusion.
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The influences of diabetes on cytoplasmic and membranous GLUT4 protein level were examined in the age-matched control- led, STZ-diabetic, and insulin-treated diabetic rats with or without I/R injury Figure 4
The influences of diabetes on cytoplasmic and membranous GLUT4 protein level were examined in the age-
matched controlled, STZ-diabetic, and insulin-treated diabetic rats with or without I/R injury. Equal amounts of 
proteins were resolved on 10% SDS-PAGE and blotted with respective GLUT4 antibodies. All experiments were performed in 
triplicates from six animals (*, vs. CS; †, vs. DMS; ‡, vs. C; n = 6 per group). Upper panels show blots, and quantified ratio is 
shown in the lower panels. C, age-matched control; CS, control sham; DM, STZ-induced diabetes; DMS, DM sham; DMI, diabe-
tes treated with insulin (4 IU/day for 5 days); DMIS, DMI sham; I/R, myocardial ischemia 1 h following by a 3 h of reperfusion.
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The influences of diabetes on Akt and phosphorylated protein level were examined in the age-matched controlled, STZ-dia- betic, and insulin-treated diabetic rats with or without I/R injury Figure 5
The influences of diabetes on Akt and phosphorylated protein level were examined in the age-matched con-
trolled, STZ-diabetic, and insulin-treated diabetic rats with or without I/R injury. Equal amounts of proteins were 
resolved on 10% SDS-PAGE and blotted with respective Akt, p-ser 473-Akt, and p-thr 308-Akt antibodies. All experiments 
were performed in triplicates from six animals (*, vs. CS; †, vs. DMS; ‡, vs. C; n = 6 per group). Upper panels show blots, and 
quantified ratio is shown in the lower panels. C, age-matched control; CS, control sham; DM, STZ-induced diabetes; DMS, DM 
sham; DMI, diabetes treated with insulin (4 IU/day for 5 days); DMIS, DMI sham; I/R, myocardial ischemia 1 h following by a 3 h 
of reperfusion.
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levels was elevated. Increasing glucose uptake may possi-
bly shift myocardial metabolism from long chain fatty
acid (LCFA) to glucose oxidation during reperfusion,
which is more oxygen efficient and prevents the produc-
tion of toxic LCFA intermediates. As seen from the rat
models, diabetes seemed to blunt those compensatory
effects. This may be the explanation for the low contractil-
ity and high mortality found in diabetic rats with I/R
injury.
The in-vivo animal and human studies have clearly shown
that diabetes and insulin resistance aggravate myocardial
ischemic injury. However, many experimental studies
using animal models of diabetes show widely varied
results ranging from no change, increased, or decreased
sensitivity of ischemia with or without reperfusion injury
[37-41]. Our study provided systemic in-vivo evidence in
different structural levels to explain how diabetes can
aggravate myocardial I/R injury and revealed the role of
insulin signaling. Our results show that diabetes with I/R
injury reduced Akt/GLUT4 signaling (molecule level)
without exacerbating myocardial infarction (tissue level)
and arrhythmias (organ level), attenuated ventricular con-
tractility (organ level), and raised mortality rate (organ-
ism system).
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